Quantitative mpMRI to predict metastatic potential of prostate cancer
- Conditions
- Prostate CancerProstate carcinoma10038597
- Registration Number
- NL-OMON51200
- Lead Sponsor
- Radboud Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 30
- Histologically proven primary cancer of the prostate, based on prostate
biopsy-core analysis.
- Patient is scheduled and fit for PSMA-PET/CT
- Age*50 years. Ability to give voluntary written informed consent to
participate in this study.
- Contraindication for MRI-scanning, i.e. claustrophobia, intracranial metal
clips, metallic bodies in the eye, implanted electric and electronic devices
not eligible for MRI (pacemakers, insulin pumps, cochlear implants,
neurostimulators).
- Prior prostate cancer treatment.
- Prior pelvic surgery, associated with pelvic lymphadenopathy
- Presence of any medical condition that in the opinion of the
investigator/treating physician will affect patients* clinical status by
participating in this trial.
- Inability to lie still for 45 minutes or comply with imaging.
- The patient is already enrolled in one or more concurrent studies, which
could confound the results of this study, according to the investigators.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The main parameter of this study is the feasibility of MRI, as a weighted score<br /><br>of combined quantitative MRI parameters, to predict the presence of lymph node<br /><br>metastases in prostate cancer. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary endpoints comprise established thresholds in individual quantitative<br /><br>MRI parameters separating localized from (oligo-)metastatic disease.</p><br>